Diamond Therapeutics Inc., a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, announces the successful completion of its Phase I clinical study of low-dose psilocybin. Regulated by Health Canada, Diamond’s study is the first randomized, double-blind, and placebo-controlled single ascending dose study to investigate low doses of…